Auris Medical (EARS) Sees Unusually-High Trading Volume
Shares of Auris Medical Holding AG (NASDAQ:EARS) saw unusually-strong trading volume on Thursday . Approximately 11,097,396 shares changed hands during mid-day trading, an increase of 1,933% from the previous session’s volume of 545,819 shares.The stock last traded at $0.62 and had previously closed at $0.47.
Separately, Zacks Investment Research upgraded Auris Medical from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Wednesday, August 30th.
The company has a market capitalization of $23.26, a PE ratio of -0.97 and a beta of 0.59. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86.
A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC bought a new position in Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical at the end of the most recent reporting period. 25.15% of the stock is owned by institutional investors.
About Auris Medical
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.